Although the clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR-T cells was limited due to respiratory toxicity and short persistence [20], new generations of CEA CAR-T cells are currently being evaluated in GC patients. This evidence concerns the gene CEACAM5 and gastric cancer.